Skip to main content
. Author manuscript; available in PMC: 2009 Jan 2.
Published in final edited form as: Neurobiol Dis. 2006 Sep 27;25(1):45–53. doi: 10.1016/j.nbd.2006.08.007

Figure 2. Erythropoietin further enhances the phosphorylation of STAT5 in hippocampal CA1 during the early stage after global cerebral ischemia in rats.

Figure 2

(A) Representative Western blots showing the expression of EPO receptor in rat CA1 regions. (B) Representative Western blots showing the protein levels of phosphorylated and total STAT5 in the CA1 at early time points following ischemia from S (sham-operated), V (vehicle-treated ischemia) and E (EPO-treated 20 min after ischemia) groups. (C) The average levels of phospho-STAT5 in the CA1 region determined by Western blot were increased in the EPO-treated ischemia group at 1 and 3 hr following global ischemia compared to the vehicle-treated ischemia group. Data are mean ± SEM, assessed by ANOVA and post hoc Scheffe’s tests. *P<0.05 vs. vehicle-treated ischemia group at the same time point. (D) Representative Western blots showing protein levels of phosphorylated and total STAT5 in the CA1 region at 3 hr following ischemia. Sham, sham-operated animal; Veh., vehicle-treated ischemia; EPO, EPO treatment (50 Units, 20 min after ischemia); EPO+AG, EPO and AG490-treated ischemia (50 Units of EPO and 2.5 μg of AG490, 20 min after ischemia). (E) Western blots of phospho-STAT5 in CA1 at 3 hr after global ischemia were quantified, showing that AG490 blocked the EPO-enhanced phosphorylation of STAT5. Data are mean ± SEM, assessed by ANOVA and post hoc Scheffe’s tests. *P<0.05 vs. vehicle group, # P<0.05 vs. EPO group, >0.05 vs. vehicle group.